STOCK TITAN
  1. Home
  2. News
  3. ACONW

Aclarion Inc - ACONW STOCK NEWS

Welcome to our dedicated news page for Aclarion (Ticker: ACONW), a resource for investors and traders seeking the latest updates and insights on Aclarion.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aclarion's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aclarion's position in the market.

News
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
Rhea-AI Summary
Aclarion, Inc. confirms the predictive value of Nociscan for identifying painful discs. Nociscan demonstrated 100% sensitivity and 80% specificity compared to provocative discography, providing surgeons with better information. The clinical paper published in the International Journal of Spine Surgery establishes Nociscan as a noninvasive method to identify painful lumbar discs, potentially improving surgical outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.18%
Tags
none
-
News
Aclarion Announces Closing of $3.0 Million Public Offering
Rhea-AI Summary
Aclarion, Inc. closes public offering of 5,175,000 units, raising approximately $3.0 million. Each unit sold at $0.58 includes one share of common stock (or pre-funded warrant), and two common warrants. The common warrants are exercisable at $0.58 per share and expire in five years. Maxim Group LLC acted as the sole placement agent. The offering was made under a registration statement declared effective by the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
offering
-
News
Aclarion Announces Pricing of $3.0 Million Public Offering
Rhea-AI Summary
Aclarion, Inc. announced the pricing of a public offering of 5,175,000 units at $0.58 per unit, expecting gross proceeds of approximately $3.0 million. The offering includes common stock, pre-funded warrants, and common warrants, with Maxim Group LLC acting as the sole placement agent. The offering is expected to close on February 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.55%
Tags
offering
News
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
Rhea-AI Summary
Aclarion, Inc. (ACON) has initiated the CLARITY trial to validate superior surgical outcomes using Nociscan technology. The recent financing transactions have significantly reduced debt and increased available cash, enabling the company to achieve key milestones. The strategic partnership with Alphatec is expected to onboard 5 additional Key Opinion Leader surgeons and increase Nociscan orders. The CLARITY trial will enroll up to 300 patients across 8 sites, with principal investigator Nicholas Theodore, MD, leading the study. Aclarion also aims to add 5 new KOL surgeons to the Nociscan network in the first half of 2024 through the strategic partnership with Alphatec.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
partnership
-
News
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
Rhea-AI Summary
Aclarion, Inc. announces the availability of Nociscan, their diagnostic solution for chronic low back pain, at the Barrow Neurological Institute in Phoenix, AZ. Dr. Juan Uribe, a renowned neurosurgeon, is now the 3rd key opinion leader with access to the diagnostic center. Nociscan aims to help physicians identify the location of chronic low back pain noninvasively through chemical biomarkers and proprietary algorithms. The activation of the Phoenix market is expected to support scan volume growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
none
-
News
Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution
Rhea-AI Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW) announced the product release of Nociscan 2.6, expanding accessibility on the worldwide MRI market. This new release includes support for additional leading MRI scanners beyond those manufactured by Siemens, a major milestone towards making Nociscan available on the leading MRI machines of all manufacturers. The company aims to improve the lives of millions of patients suffering from degenerative spine disease and low back pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.7%
Tags
none
News
Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan
Rhea-AI Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW) partners with Alphatec Spine, Inc. (Nasdaq: ATEC) to integrate Aclarion’s Nociscan technology, the first augmented intelligence platform to measure pain biomarkers in the lumbar spine, into ATEC’s AlphaInformatiX platform. The partnership aims to improve clinical outcomes and reduce procedural costs for patients with chronic low back pain, leveraging ATEC’s surgeon network and providing ATEC with exclusive distribution rights for Nociscan. Aclarion’s published trials confirm the comparative advantage of Nociscan in achieving differentiated surgical outcomes, with a peer-reviewed publication demonstrating an 85% success rate at two years for discogenic low back pain surgeries consistent with Nociscan-identified discs, compared to 63% for inconsistent treatment strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
partnership
-
News
Aclarion Announces Reverse Stock Split
Rhea-AI Summary
Aclarion, Inc. (Nasdaq: ACON, ACONW) announced a 1-for-16 reverse stock split effective before market open on January 4, 2024, to meet Nasdaq listing standards. The split will increase the per share price and bid price of its common stock above the $1.00 required by Nasdaq’s Minimum Bid Price Rule.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1559.2%
Tags
none
-
News
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
Rhea-AI Summary
Aclarion, Inc. (ACON) has completed 1,000 commercial Nociscan exams, with the pace of commercial adoption accelerating. The company's CEO, Brent Ness, highlighted the achievement and the strategy that led to it. Aclarion's Chief Strategy Officer, Ryan Bond, emphasized the importance of Nociscan in transforming complex data into individualized biomarker reports for chronic low back pain patients. The company holds a disruptive innovation with a strong patent portfolio and aims to address the high healthcare spending on low back and neck pain in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
Rhea-AI Summary
Aclarion (ACON) successfully enrolls 10 leading spine surgery KOLs to drive Nociscan to standard of care for identifying discogenic low back pain. The company will activate MRIs for each KOL surgeon to expand Nociscan access and demonstrate clinical outcome improvements to payers, with initial scan volume data to be released by the end of the year. The recruitment of renowned KOL surgeons is a critical step in establishing Nociscan as the standard of care for diagnosing and treating low back pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none
Stock ACONW logo
Aclarion Inc

Nasdaq:ACONW

ACONW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ACONW Stock Data

1.93M
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States
Broomfield